Clinical trial · Observational
Multiple Myeloma Extramedulary Disease Samples FFPE
Discovery And Validation Of New Biomarkers In The Context Of Multiple Myeloma Extramedulary Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with extramedullary multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment. No intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma and Malignant Plasma Cell Neoplasms | — | UNRESOLVED | — |
| Multiple Myeloma Survival Outcome | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- FFPE Blocks
- description
- Samples obtained from patients with multiple myeloma extramedullary disease. The samples should be obtained in the extramedullary disease.
Primary outcomes (1)
- measure
- Feasibility of cohort inclusion based on availability of FFPE tissue and confirmed extramedullary disease.
- timeFrame
- Baseline
- description
- Number of participants who meet both criteria: * confirmation of extramedullary disease using predefined clinical and histopathological criteria, and * availability of an adequate FFPE tissue block suitable for inclusion. Feasibility will be quantified by reporting the proportion of eligible participants among all patients screened for potential inclusion.
Secondary outcomes (1)
- measure
- Evaluate FFPE analytical quality through expression rates of predefined IHC markers (CD138, CD56, MUM1, light chains).
- timeFrame
- Baseline
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with histologically confirmed extramedullary myeloma (excluding plasmacytoma). * Availability of a representative FFPE block from a surgical specimen. * Diagnosis established within the past 10 years. * Availability of associated clinical and follow-up data. Exclusion Criteria: * Patients with plasmacytoma only. * Insufficient or non-representative FFPE material. * Missing key diagnostic or clinical data.
References
Publications (0)
Data not yet available